6Natarajan P, Ray KK, Cannon CP. High-density lipoprotein and coronary heart disease: current and future therapies [J]. J Am Coil Cardiol, 2010, 55 (13):1283-1299.
7Alagona P Jr. Beyond LDL cholesterol: the role of elevated tri glycerides and low HDI. cholesterol in residual CVD risk remai ning after statin therapy [J]. Am J Manag Care, 2009, 15 (3 Suppl) : S65-73.
8Chapman MJ, Redfem JS, McGovem ME, et al. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascu lar risk [J]. Pharmacol Ther, 2010, 126 (:3) : 314-345.
9Reiner Z. Combined therapy in the treatment of dyslipidemia [J]. Fundam Clin Pharmacol, 2010, 24 (1):19-28.
10Judge EP, Phelan D, O'Shea D. Beyond statin therapy: a re view of the management of residual risk in diabetes mellitus[J]. J R Soc Med, 2010, 103 (9): 357-362.
